Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $985.10M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.83M
Average 1.07M
VOR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Vor Biopharma Inc.NASDAQ: VOR
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$219.56M, compared with -$31.66M a year earlier. Trailing-twelve-month EBITDA was $449.13M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -511.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$219.56M-112.7% QoQ
- Last fiscal yearDec 2025
- -$693.09M-511.3% YoY
- LTMMar 2026
- $449.13M+489.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -593.5% | +100.0% | +693.5 pp |
| 1 year | -511.3% | +100.0% | +611.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (693.09M) USD
- Year-over-year change
- -511.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (693.09M) | -511.3% |
| FY2024 | 2024-12-31 | (113.39M) | +0.9% |
| FY2023 | 2023-12-31 | (114.37M) | -37.6% |
| FY2022 | 2022-12-31 | (83.13M) | -23.2% |
| FY2021 | 2021-12-31 | (67.47M) | — |
EBITDA vs competitors
How VOR compares with its peers on the latest reported figures
- VOR's LTM Mar 2026 EBITDA of $449.13M is the highest of the 10 companies compared; the peer median is -$187.06M.
- Its year-over-year change of +489.9% is the highest of 10, against a peer median of +10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $449.13M | +489.9% | — | — | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| LTM Mar 2026 | -$90.7M | +10.7% | — | — | |
| LTM Mar 2026 | -$100.08M | +56.8% | — | 258.7% | |
| LTM Mar 2026 | -$117.42M | +23.4% | — | 1859.1% | |
| LTM Mar 2026 | -$187.06M | +2.3% | — | — | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$230.8M | +3.4% | — | 249.3% | |
| LTM Mar 2026 | -$384.61M | +25.4% | — | 581.9% | |
| LTM Sep 2026 | -$482.67M | -3.6% | — | 1917.5% | |
| Peer median (excluding VOR) | -$187.06M | +10.7% | — | 581.9% | |
Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 8.96M | 3.49M | 0 | 0 |
| Gross Profit | 0 | (8.96M) | (3.49M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 47.53M | 64.55M | 94.32M | 93.31M | 321.53M |
| Selling, General & Admin | 21.49M | 19.91M | 31.72M | 27.88M | 50.11M |
| Operating Expenses | 69.02M | 84.46M | 122.54M | 121.19M | 371.64M |
| Depreciation & Amortization | 1.43M | 8.96M | 3.49M | 3.53M | 2.89M |
| EBITDA | (67.47M) | (83.13M) | (114.37M) | (113.39M) | (693.09M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (69.02M) | (93.42M) | (126.04M) | (121.19M) | (371.64M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 119K | 1.32M | 8.17M | 4.27M | 5.87M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 119K | 1.32M | 8.17M | 4.27M | (324.34M) |
| Income Before Tax | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (37.80) | (46.60) | (35.00) | (34.00) | (70.50) |
| EPS (Diluted) | (37.80) | (46.60) | (35.00) | (34.00) | (70.50) |
| Weighted Avg Shares | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M |
| Weighted Avg Shares (Diluted) | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M |
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$18.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.